Atossa Therapeutics
Atossa Therapeutics
ATOS
NASDAQ
1.37
USD
44.21%
About
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer.
(Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations.
It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 572.7K |
| Three Month Average Volume | 22.0M |
| High Low | |
| Fifty-Two Week High | 2.31 USD |
| Fifty-Two Week Low | 0.62 USD |
| Fifty-Two Week High Date | 05 Apr 2024 |
| Fifty-Two Week Low Date | 13 Nov 2023 |
| Price and Volume | |
| Current Price | 1.37 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 6.29% |
| Thirteen Week Relative Price Change | -1.54% |
| Twenty-Six Week Relative Price Change | 24.60% |
| Fifty-Two Week Relative Price Change | 38.41% |
| Year-to-Date Relative Price Change | 31.47% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | 5.38% |
| Twenty-Six Week Price Change | 37.00% |
| Five Day Price Change | -3.52% |
| Fifty-Two Week Price Change | 73.44% |
| Year-to-Date Price Change | 55.68% |
| Month-to-Date Price Change | 1.48% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.72636 USD |
| Book Value Per Share (Most Recent Quarter) | 0.63743 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.72636 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.63743 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.24333 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.23869 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.20642 USD |
| Normalized (Last Fiscal Year) | -0.21497 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.23869 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.20642 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.23869 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.20642 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.70596 USD |
| Cash Per Share (Most Recent Quarter) | 0.63238 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.2385 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.20619 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.14888 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -13.57% |
| Tangible Book Value (5 Year) | 59.91% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -33.90% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 38.03% |
| EPS Change (Trailing Twelve Months) | 17.32% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -79,526,000 |
| Net Debt (Last Fiscal Year) | -88,460,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 18 |
| Current Ratio (Most Recent Quarter) | 14 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -20,955,000 |
| Free Cash Flow (Trailing Twelve Months) | -18,690,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -27.39% |
| Return on Assets (Trailing Twelve Months) | -26.68% |
| Return on Assets (5 Year) | -29.97% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -28.88% |
| Return on Equity (Trailing Twelve Months) | -28.09% |
| Return on Equity (5 Year) | -34.21% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -28.80% |
| Return on Investment (Trailing Twelve Months) | -28.00% |
| Return on Investment (5 Year) | -32.55% |